Meeting
2023 ASCO Annual Meeting
INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC).
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Dejan Juric , Kevin Kalinsky , Seock-Ah Im , Eva M Ciruelos , Giampaolo Bianchini , Carlos H. Barrios , William Jacot , Peter Schmid , Sherene Loi , Hope S. Rugo , Veronica Craine , Katherine E. Hutchinson , Aulde Flechais , Eirini Thanopoulou , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT05646862
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS1123)
DOI
10.1200/JCO.2023.41.16_suppl.TPS1123
Abstract #
TPS1123
Poster Bd #
338a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
First Author: Jose Baselga
First Author: Michelino De Laurentiis
First Author: Cristina I. Truica
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
First Author: Dejan Juric